41034-52-0

Usage

Chemical Properties

White to off-white powder

InChI:InChI=1/C10H11NO2/c12-10(13)9-8-4-2-1-3-7(8)5-6-11-9/h1-4,9,11H,5-6H2,(H,12,13)

Upstream product

• 486-73-7 1-isoquinolinecarboxylic acid 
• 844-25-7 2-benzoyl-1-cyano-1,2-dihydroisoquinoline 

Downstream Products

• 111157-56-3 2,3,3aα,4β,6,11,11aα,11bα-octahydro-2-methyl-4-(2-phenylethyl)-1H-pyrrolo<3',4':3,4>pyrrolo<1,2-b>isoquinoline-1,3-dione 
• 111157-56-3 2,3,3aα,4α,6,11,11aβ,11bα-octahydro-2-methyl-4-(2-phenylethyl)-1H-pyrrolo<3',4':3,4>pyrrolo<1,2-b>isoquinoline-1,3-dione 
• 111016-18-3 2,3,3aα,4α,6,11,11aβ,11α-octahydro-2-methyl-4-(4-nitrophenyl)-1H-pyrrolo<3',4':3,4>pyrrolo<1,2-b>isoquinoline-1,3-dione 
• 111016-18-3 2,3,3aα,4β,6,11,11aβ,11bα-octahydro-2-methyl-4-(4-nitrophenyl)-1H-pyrrolo<3',4':3,4>pyrrrolo<1,2-b>isoquinoline-1,3-dione 
• 111016-18-3 2,3,3aα,4β,6,11,11aα,11bα-octahydro-2-methyl-4-(4-nitrophenyl)-1H-pyrrolo<3',4':3,4>pyrrolo<1,2-b>isoquinoline-1,3-dione 
• 111016-17-2 2,3,3aα,4α,6,11,11aβ,11bα-octahydro-4-(4-dimethylaminophenyl)-2-methyl-1H-pyrrolo<3',4':3,4>pyrrolo<1,2-b>isoquinoline-1,3-dione 
• 111016-17-2 2,3,3aα,4β,6,11,11aα,11bα-octahydro-4-(4-dimethylaminophenyl)-2-methyl-1H-pyrrolo<3',4':3,4>pyrrolo<1,2-b>isoquinoline-1,3-dione 
• 32909-74-3 1-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline 
• 35264-05-2 2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetic acid 
• 166591-85-1 (±)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 153758-56-6 (1,2,3,4-tetrahydroisoquinolin-1-yl)methanol 
• 144149-81-5 N-(4-chlorobenzoyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 144149-82-6 N-(4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 106181-28-6 ethyl (+/-)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate 

Relevant academic research and scientific papers

1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.

Lipase-catalyzed kinetic and dynamic kinetic resolution of 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid

A dynamic kinetic resolution method for the preparation of enantiopure 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid (R)-2 was developed involving the CAL-B-catalyzed enantioselective hydrolysis of the corresponding ethyl ester (±)-1 in toluene/acetonitrile (4:1) containing 1 equiv of added water and 0.25 equiv of dipropylamine. This method allowed the preparation of (R)-2 (ee = 96%) with 80% isolated yield. The kinetic resolution of (±)-1 in diisopropyl ether at 3 °C afforded both enantiomers with ee ≥92%.

Kinetic resolution of protected α-amino acid derivatives by a chiral O-nucleophilic acyl transfer catalyst

The kinetic resolution of α-trifluoroacetamido N-acyl oxazolidinethiones using 5-10% of the chiral, nonracemic O-nucleophilic acyl transfer catalyst 2 is described. A variety of substrates participate in this reaction in excellent yields, with s-factors ranging from 20 to 86. Copyright

SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS

The invention relates to compounds of formula (I), wherein R1, R2, R3, R4, A, n and L have the significances indicated in the description. The use of the inventive compounds in the form of drags for preventing and/or treating diseases in which progression an active reinforced matrix-metalloproteinases take part is also disclosed.

Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores

Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(α-methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the α-methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50 = 5.8 mg kg-1, TD50 = 36.4 mg kg-1, PI = 6.3). Replacement of the piperidine ring of 1 by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man.

Boronic ester and acid compounds, synthesis and uses

Disclosed herein are boronic ester and acid compounds, their synthesis and uses. More specifically, disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds.

BORONIC ESTER AND ACID COMPOUNDS

Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Synthesis and biological activities of a novel class of azole-containing antifungal agents

A series of novel 1,2,3,4-tetrahydroisoquinoline derived azoles has been designed and synthesized as antifungal agents which might function as inhibitors of cytochrome P-450 dependent lanosterol 14α-demethylase. In vitro tests showed that some of these compounds, especially 5b and 6b, effectively inhibit the growth of several strains of yeasts as well as molds.